Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2009-03-06
2010-06-29
Horlick, Kenneth R. (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07745137
ABSTRACT:
It is intended to provide a means of diagnosing myocardial infarction which shows a high accuracy and a high predictability. The risk of myocardial infarction is diagnosed by a method comprising the following steps: (i) the step of analyzing 2 or more polymorphisms among 10 gene polymorphisms or 5 gene polymorphisms proved as relating to myocardial infarction; (ii) the step of determining the genotype of a nucleic acid sample based on the polymorphism data obtained in the above step; and (iii) the step of determining the genetic risk of myocardial infarction from the genotype thus obtained.
REFERENCES:
patent: 2004/0005566 (2004-01-01), DePhillipo et al.
patent: 2005/0026169 (2005-02-01), Cargill et al.
patent: 2005/0089914 (2005-04-01), Yamasaki
patent: 2007/0042382 (2007-02-01), Cargill et al.
patent: WO-91/13075 (1991-09-01), None
patent: WO-01/18250 (2001-03-01), None
patent: WO-01/79234 (2001-10-01), None
patent: WO-03/087360 (2003-10-01), None
Terashima et al., Circulation 99, 2717-2719 (1999).
M.E. Marenberg, et al.; “Genetic Susceptibility to Death From Coronary Heart Disease in a Study of Twins;”The New England Journal of Medicine; vol. 330; No. 15; Apr. 14, 1994; pp. 1041-1046.
J.J. Nora, et al:; “Genetic-Epidemiologic Study of Early-onset Ischemic Heart Disease;”Circulation; vol. 61; No. 3; Mar. 1980; pp. 503-508.
U. Broeckel, et al.; “A comprehensive linkage analysis for myocardial infarction and its related risk factors;”Nature Genetics; vol. 30; Feb. 2002; pp. 210-214.
F. Cambien, et al.; “Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction;”Nature; vol. 359; Oct. 15, 1992; pp. 641-644.
E. J. Weiss, et al; “A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis;”The New England Journal of Medicine; vol. 334; No. 17; Apr. 25, 1996; pp. 1090-1094.
L. Iacoviello, et al.; “Polymorphisms in the Coagulation Factor VII Gene and the Risk of Myocardial Infarction;”The New England Journal of Medicine; vol. 338; No. 2; Jan. 8, 1998; pp. 79-85.
J.A. Kuivenhoven, et al., “The Role of a Common Variant of the Cholesterol Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis;”The New England Journal of Medicine; vol. 338; No. 2; Jan. 8, 1998; pp. 86-93.
M. Boerma, et al.; “A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development;”Journal of Internal Medicine; vol. 246; 1999; pp. 211-218.
N. Inoue, et al.; “Polymorphism of the NADH/NADPH Oxidasep22 phoxGene in Patients With Coronary Artery Disease;”Circulation; vol. 97; 1998; pp. 135-137.
E.J. Topol, et al; “Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction;”Circulation; vol. 104; Nov. 27, 2001; pp. 2641-2644.
T. Skoog, et al.; “A common functional polymorphism (C→A substitution at position-863) in the promotor region of the tumour necrosis factor-α (TNF-α) gene associated with reduced circulating levels of TNF-α;”Human Molecular Genetics; vol. 8; No. 8; 1999; pp. 1443-1449.
Y. Yamada, et al.; “Identification of the G994→T Missense Mutation in Exon 9 of the Plasma Platelet-Activating Factor Acetylhydrolase Gene as an Independent Risk Factor for Coronary Artery Disease in Japanese Men;”Metabolism; vol. 47; No. 2; Feb. 1998; pp. 177-181.
W. Koch, et al.; “Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction;”Artherosclerosis; vol. 159; 2001; pp. 137-144.
I. Inoue, et al.; “A Nucleotide Substitution in the Promotor of Human Angiotensinogen Is Associated with Essential Hypertension and Affects Basal Transcription In Vitro;”J. Clin. Invest; vol. 99; No. 7; Apr. 1997; pp. 1786-1797.
J.-C. Lambert, et al.; “Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study;”Human Molecular Genetics; vol. 9; No. 1; 2000; pp. 57-61.
M. Eto, et al.; “Increased frequencies of apolipoprotein ε2 and ε4 alleles in patients with ischemic schemic heart disease;”Clinical Genetics; vol. 36; 1989; pp. 183-188.
J. Ruiz, et al.; “Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes;”The Lancet; vol. 346; Sep. 30, 1995; pp. 869-872.
M. Murata, et al.; “Coronary Artery Disease and Polymorphisms in a Receptor Mediating Shear Stress-Dependent Platelet Activation;”Circulation; vol. 96; No. 10; Nov. 18, 1997; pp. 3281-3286.
P. Eriksson, et al.; “Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction;”Proc. Natl. Acad. Sci. USA; vol. 92; Mar. 1995; pp. 1851-1855.
S. Ye, et al.; “Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis;”Br Heart J; vol. 73; 1995; pp. 209-215.
R.W. Mahley; “Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology;”Science; vol. 240; Apr. 29, 1988; pp. 622-630.
W.J. Schneider, et al.; “Familial Dysbetalipoproteinemia. Abnormal Binding of Mutant Apoprotein E to Low Density Lipoprotein Receptors of Human Fibroblasts and Membranes from Liver and Adrenal of Rats, Rabbits, and Cows;”J. Clin. Invest.; vol. 68; Nov. 1981; pp. 1075-1085.
R.E. Gregg, et al.; “Type III Hyperlipoproteinemia: Defective Metabolism of an Abnormal Apolipoprotein E;”Science; vol. 211; Feb. 6, 1981; pp. 584-586.
J.L. Breslow, et al.; “Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2;”Journal of Lipid Research; vol. 23; 1982; pp. 1224-1235.
P.M. Sullivan, et al.; “Type III Hyperlipoproteinemia and Spontaneous Atherosclerosis in Mice Resulting from Gene Replacement of MouseApoewith HumanAPOE*2;” The Journal of Clinical Investigation; vol. 102; No. 1; Jul. 1998; pp. 130-135.
S.S. Kumari, et al.; “Functional Expression and Biophysical Properties of Polymorphic Variants of the Human Gap Junction Protein Connexin37;”Biochemical and Biophysical Research Communications; vol. 274; No. 1; 2000; pp. 216-224.
E. Dupont, et al.; “Altered Connexin Expression in Human Congestive Heart Failure;”J Mol Cell Cardiol; vol. 33; 2001; pp. 359-371.
S. Kumari, et al.; “Two Polymorphic Variants of Human Connexin37 Exhibit Different Biophysical Properties;”Molecular Biology of the Cell; vol. 9 (Suppl.); Nov. 1998; pp. 93a 538.
K.E. Reed, et al.; “Molecular cloning and functional expression of human connexin37, an endothelial cell gap junction protein;”J. Clin. Invest.; vol. 93; No. 2; 1993; pp. 997-1004.
The European Patent Office Communication (including Supplementary Partial European Search Report) for corresponding European patent application No. 03712817(PCT/JP0303477), dated Oct. 13, 2005.
Hung-I. Yeh, et al. “Connexin37 gene polymorphism and coronary artery disease in Taiwan;”International Journal of Cardiology; vol. 81, pp. 251-255 (2001).
Werner Koch, et al. “Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction;”Atherosclerosis; vol. 159, pp. 137-144 (2001).
M. Boerma, et al. “A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development;”Journal of Internal Medicine; vol. 246, pp. 211-218 (1999).
Elvis Brscic, et al. “Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synt
Yamada Yoshiji
Yokota Mitsuhiro
Edwards Angell Palmer & & Dodge LLP
Horlick Kenneth R.
Nagoya Industrial Science Research Institute
LandOfFree
Method of diagnosing risk of myocardial infarction by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of diagnosing risk of myocardial infarction by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosing risk of myocardial infarction by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240989